PDUFA date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT)- Commercial capabilities ...

Milestone Pharmaceuticals (MIST) provided a corporate update and outlined its strategic priorities for 2025. CARDAMYST for Paroxysmal ...

PDUFA date of March 27, 2025 for CARDAMYST (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT) - Commercial capabilities build out in process, with proposed launch in PSVT targe ...

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and a price target of $25.00 on Milestone Pharmaceuticals, traded on NASDAQ under the ticker (NASDAQ:MIST). The stock has shown strong ...

supraventricular tachycardia, ventricular bigeminy, ventricular extrasystoles Required intervention 77 (07/09/2001) 23, M Droperidol 50 mg i.m., haloperidol 10 mg i.m., levomepromazine ...

A GPS smartwatch that helps beginners gamify their fitness with car-like data and takes elite athletes to new levels.

At least two deaths and over a hundred injuries have been linked to a malfunctioning heart monitoring device from Philips and its subsidiary, Braemer. The company affirmed in a statement that that the ...

Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research report issued to clients and investors on ...

Such techniques can be automatically applied using implantable cardioverter defibrillators (ICDs) and offer the potential for painless termination of ventricular tachycardia (VT). Reduction in ...

Over 80% of these fatalities result from heart attacks and strokes. December is notorious for being the biggest month for heart attacks, with one of the most dangerous being the widowmaker heart ...

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.